Neoadjuvant chemoradiotherapy for stage III non-small cell lung cancer

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

The local management of stage III non-small cell lung cancer is controversial. Although definitive chemoradiotherapy (CRT) is considered a standard-of-care in the curative management of the disease, inadequate local control outcomes have led to various treatment strategies that incorporate surgical resection. Surgery alone has long been recognized as insufficient for this stage, and thus neoadjuvant strategies have been developed to treat micrometastatic disease and increase the probability of a complete resection. The optimal induction strategy has not yet been defined, however, with arguments favoring either preoperative chemotherapy or CRT. In this article, the data supporting the use of neoadjuvant CRT and the randomized literature comparing the two approaches will be reviewed. The article will conclude with summary comparisons of these induction paradigms.

Original languageEnglish (US)
Article number281
JournalFrontiers in Oncology
Volume7
Issue numberDEC
DOIs
StatePublished - Dec 4 2017

Fingerprint

Chemoradiotherapy
Non-Small Cell Lung Carcinoma
Standard of Care
Disease Management
Drug Therapy
Therapeutics

Keywords

  • Combined modality therapy
  • Lung cancer
  • Neoadjuvant therapy
  • Radiation therapy
  • Stage III non-small cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Neoadjuvant chemoradiotherapy for stage III non-small cell lung cancer. / Sher, David J.

In: Frontiers in Oncology, Vol. 7, No. DEC, 281, 04.12.2017.

Research output: Contribution to journalReview article

@article{b05e3c5dff37428495a9a4c9a566dfc5,
title = "Neoadjuvant chemoradiotherapy for stage III non-small cell lung cancer",
abstract = "The local management of stage III non-small cell lung cancer is controversial. Although definitive chemoradiotherapy (CRT) is considered a standard-of-care in the curative management of the disease, inadequate local control outcomes have led to various treatment strategies that incorporate surgical resection. Surgery alone has long been recognized as insufficient for this stage, and thus neoadjuvant strategies have been developed to treat micrometastatic disease and increase the probability of a complete resection. The optimal induction strategy has not yet been defined, however, with arguments favoring either preoperative chemotherapy or CRT. In this article, the data supporting the use of neoadjuvant CRT and the randomized literature comparing the two approaches will be reviewed. The article will conclude with summary comparisons of these induction paradigms.",
keywords = "Combined modality therapy, Lung cancer, Neoadjuvant therapy, Radiation therapy, Stage III non-small cell lung cancer",
author = "Sher, {David J.}",
year = "2017",
month = "12",
day = "4",
doi = "10.3389/fonc.2017.00281",
language = "English (US)",
volume = "7",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media S. A.",
number = "DEC",

}

TY - JOUR

T1 - Neoadjuvant chemoradiotherapy for stage III non-small cell lung cancer

AU - Sher, David J.

PY - 2017/12/4

Y1 - 2017/12/4

N2 - The local management of stage III non-small cell lung cancer is controversial. Although definitive chemoradiotherapy (CRT) is considered a standard-of-care in the curative management of the disease, inadequate local control outcomes have led to various treatment strategies that incorporate surgical resection. Surgery alone has long been recognized as insufficient for this stage, and thus neoadjuvant strategies have been developed to treat micrometastatic disease and increase the probability of a complete resection. The optimal induction strategy has not yet been defined, however, with arguments favoring either preoperative chemotherapy or CRT. In this article, the data supporting the use of neoadjuvant CRT and the randomized literature comparing the two approaches will be reviewed. The article will conclude with summary comparisons of these induction paradigms.

AB - The local management of stage III non-small cell lung cancer is controversial. Although definitive chemoradiotherapy (CRT) is considered a standard-of-care in the curative management of the disease, inadequate local control outcomes have led to various treatment strategies that incorporate surgical resection. Surgery alone has long been recognized as insufficient for this stage, and thus neoadjuvant strategies have been developed to treat micrometastatic disease and increase the probability of a complete resection. The optimal induction strategy has not yet been defined, however, with arguments favoring either preoperative chemotherapy or CRT. In this article, the data supporting the use of neoadjuvant CRT and the randomized literature comparing the two approaches will be reviewed. The article will conclude with summary comparisons of these induction paradigms.

KW - Combined modality therapy

KW - Lung cancer

KW - Neoadjuvant therapy

KW - Radiation therapy

KW - Stage III non-small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=85037041029&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037041029&partnerID=8YFLogxK

U2 - 10.3389/fonc.2017.00281

DO - 10.3389/fonc.2017.00281

M3 - Review article

VL - 7

JO - Frontiers in Oncology

JF - Frontiers in Oncology

SN - 2234-943X

IS - DEC

M1 - 281

ER -